[go: up one dir, main page]

CA2249348C - Preparation comprenant une combinaison de 5-methylisoxazol-4-acide carboxylique-(4-trifluoromethyl)-anilide et de n-(4-trifluoromethylphenyl)-2-cyano-3-acide hydroxycrotonique amide - Google Patents

Preparation comprenant une combinaison de 5-methylisoxazol-4-acide carboxylique-(4-trifluoromethyl)-anilide et de n-(4-trifluoromethylphenyl)-2-cyano-3-acide hydroxycrotonique amide Download PDF

Info

Publication number
CA2249348C
CA2249348C CA002249348A CA2249348A CA2249348C CA 2249348 C CA2249348 C CA 2249348C CA 002249348 A CA002249348 A CA 002249348A CA 2249348 A CA2249348 A CA 2249348A CA 2249348 C CA2249348 C CA 2249348C
Authority
CA
Canada
Prior art keywords
composition
component
compound
cancer
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002249348A
Other languages
English (en)
Other versions
CA2249348A1 (fr
Inventor
Robert Bartlett
Johann Then
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19610955A external-priority patent/DE19610955A1/de
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CA2249348A1 publication Critical patent/CA2249348A1/fr
Application granted granted Critical
Publication of CA2249348C publication Critical patent/CA2249348C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002249348A 1996-03-20 1997-03-07 Preparation comprenant une combinaison de 5-methylisoxazol-4-acide carboxylique-(4-trifluoromethyl)-anilide et de n-(4-trifluoromethylphenyl)-2-cyano-3-acide hydroxycrotonique amide Expired - Lifetime CA2249348C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19610955A DE19610955A1 (de) 1996-03-20 1996-03-20 Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
DE19610955.8 1996-03-20
PCT/EP1997/001167 WO1997034600A1 (fr) 1996-03-20 1997-03-07 Preparation comprenant une combinaison de 5-methylisoxazol-4-acide carboxylique-(4-trifluoromethyl)-anilide et de n-(4-trifluoromethylphenyl)-2-cyano-3-acide hydroxycrotonique amide

Publications (2)

Publication Number Publication Date
CA2249348A1 CA2249348A1 (fr) 1997-09-25
CA2249348C true CA2249348C (fr) 2006-10-03

Family

ID=37101799

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002249348A Expired - Lifetime CA2249348C (fr) 1996-03-20 1997-03-07 Preparation comprenant une combinaison de 5-methylisoxazol-4-acide carboxylique-(4-trifluoromethyl)-anilide et de n-(4-trifluoromethylphenyl)-2-cyano-3-acide hydroxycrotonique amide

Country Status (1)

Country Link
CA (1) CA2249348C (fr)

Also Published As

Publication number Publication date
CA2249348A1 (fr) 1997-09-25

Similar Documents

Publication Publication Date Title
AU705692B2 (en) Preparation containing a combination of 5-methylisoxazole-4 -carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide
EP0306060B1 (fr) Produits pharmaceutiques provoquant une analgésie accrue
DE3650733T2 (de) Pharmazeutische Zubereitungen und medizinische Verwendungen von Dioxopiperidinderivaten, insbesondere als Verstärker der Immunantwort sowie als antivirale und antibakterielle Wirkstoffe
KR20010075021A (ko) 불법적 용도로서 부적합한 교감신경흥분성 아민 염을포함하는 조성물
DE3627423A1 (de) Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
JPH0825879B2 (ja) 抗うつまたは抗パーキンソン病薬
EP0548103B1 (fr) Utilisation de derives de pyridylmethylsulfinyl-1h-benzimidazol pour le traitement de maladies provoquees par helicobacter
CA2249348C (fr) Preparation comprenant une combinaison de 5-methylisoxazol-4-acide carboxylique-(4-trifluoromethyl)-anilide et de n-(4-trifluoromethylphenyl)-2-cyano-3-acide hydroxycrotonique amide
KR20210042042A (ko) 페놀라민 g형 결정, 제조 방법과 그의 조성물 및 용도
IE62333B1 (en) Use of aromatic carboxylic acid amides
EP1137438B1 (fr) Formulation a spectre therapeutique elargi, contenant des inhibiteurs de la synthese des nucleotides
JPH0140009B2 (fr)
CN113677660A (zh) 乙酰水杨酸衍生物及其应用
MXPA98007564A (en) Preparation in combination containing 5-methyl-4'-trifluometil-4'-isoxazolcarboxanilide and n- (4-trifluorometilfenil) -2-cyano-3-hydroxicrotonam
GB2163957A (en) Anti-asthma compositions containing ketotifen
JPS5921615A (ja) 鎮痛剤組成物
JP4102461B2 (ja) 解熱剤
JPS5835186A (ja) ジカルボキシアミノチアゾール誘導体およびそれを含有する免疫調節組成物
HK1018742B (en) Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide
US4859658A (en) Compound compositions with improved analgesic antipyretic and anti-inflammatory activity
JP5389471B2 (ja) 鼻閉抑制剤
CN100571777C (zh) 含有adp受体拮抗剂和硝酸酯类药物的组合物
WO2005105095A1 (fr) Combinaison pour le traitement de l'hyperlipidemie
DE2053234A1 (de) Thiazolidin 4 carbonsaure enthal tende entzündungshemmende Zubereitungen
JPH0572364B2 (fr)

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170307